STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET.
A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.
The presentation will be given in English.
Link to the webcast: Calliditas Therapeutics Q1 Report 2024 (financialhearings.com)
To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50047214
After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel. +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The information was sent for publication, through the agency of the contact person set out above, on 16 May, 2024, at 8:30 a.m. CET.
Last Trade: | US$40.00 |
Daily Volume: | 0 |
Market Cap: | US$1.080B |
August 13, 2024 July 26, 2024 June 18, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB